Monitoring mycophenolate levels for lupus kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests whether checking the amount of a kidney-transplant drug (mycophenolate) in the blood helps people with lupus-related kidney disease get better treatment. It aims to improve how well the drug works while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You need a lupus diagnosis with kidney involvement (confirmed by biopsy or protein in the urine)
- You must be taking the drug mycophenolate (CellCept or generic) as part of your treatment for the past 3 months or less
- You must live in the metropolitan area of São Luís, Brazil (including São Luís, São José de Ribamar, or Paço do Lumiar)
- You cannot be pregnant or breastfeeding, and you must not have serious infections or liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how well the medicine mycophenolate mofetil (MMF) works for children and teens with lupus nephritis that is “proliferative” (a specific biopsy type). You may qualify if your kidney biopsy and current treatment match the study’s targets and you can follow frequent visits and testing.
This study tests whether mycophenolate mofetil and cyclophosphamide can improve active lupus kidney inflammation by changing immune cell patterns in your blood. It may help patients whose lupus nephritis is currently active, shown by worsening urine protein and/or kidney blood tests.
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
This study tests a new combination of two medicines (rituximab and a low dose of mycophenolate mofetil) to help children with active lupus nephritis (kidney inflammation from lupus). The goal is to see if combining these drugs works better and is safe for children.
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
This Phase 2 study tests VIB4920 to treat active lupus nephritis, a type of kidney disease caused by lupus. It may help reduce kidney inflammation and improve kidney outcomes in people with active disease despite standard care.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.